HRTS - ETF AI Analysis
Top Page
Tema Cardiovascular and Metabolic ETF (HRTS)
Rating:67Neutral
Price Target:―
Positive Factors
Healthy Recent Performance
The ETF has shown steady gains over the past month and quarter, suggesting positive short-term momentum.
Strong Healthcare Leaders in Top Holdings
Several major healthcare companies in the top positions have delivered strong year-to-date performance, helping support the fund’s returns.
Focused Exposure to Cardiovascular and Metabolic Health
The fund’s heavy tilt toward healthcare and related themes gives investors targeted exposure to a specialized area of the market.
Negative Factors
High Sector Concentration in Health Care
Nearly all of the ETF’s assets are in the healthcare sector, which increases risk if that industry faces a downturn.
Mixed Performance Among Top Holdings
Some key positions have shown weak or negative year-to-date performance, which can drag on overall fund results.
Above-Average Expense Ratio
The fund’s relatively high fee means more of the returns go to costs instead of staying with investors.
HRTS vs. SPDR S&P 500 ETF (SPY)
AUM54.25M
RegionGlobal
Expense Ratio0.75%
Beta0.64
IssuerTema
Inception DateNov 21, 2023
Dividend Yield1.29%
Asset ClassEquity
Index TrackedNo Underlying Index
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume1,710
30 Day Avg. Volume3,948
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
44.30Price Target Upside― Downside
Rating ConsensusStrong Buy
Number of Analyst Covering46
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
HRTS Summary
HRTS, the Tema Cardiovascular and Metabolic ETF, focuses on companies working on treatments and technologies for heart disease, diabetes, and other metabolic conditions. It does not track a broad market index, but instead follows this specific health care theme, mainly in U.S. stocks. Well-known holdings include Eli Lilly and UnitedHealth, along with other drug and medical science companies. Someone might invest in HRTS to tap into the long-term growth potential of innovative health care and to get targeted exposure to this niche. A key risk is that it is concentrated in one sector, so its price can rise or fall sharply with health care stocks.
How much will it cost me?The Tema Cardiovascular and Metabolic ETF (HRTS) has an expense ratio of 0.75%, meaning you’ll pay $7.50 per year for every $1,000 invested. This is higher than average because it is actively managed, focusing on a specialized niche within the health care sector.
What would affect this ETF?The HRTS ETF, focused on cardiovascular and metabolic health, could benefit from growing demand for innovative treatments as heart disease and diabetes remain global health priorities. Positive trends like advancements in biotech and pharmaceutical research, along with increased healthcare spending, may drive growth for its top holdings such as Eli Lilly and AstraZeneca. However, challenges like regulatory hurdles, patent expirations, or economic downturns affecting healthcare budgets could negatively impact the ETF's performance.
HRTS Top 10 Holdings
HRTS leans heavily into big, established health care names, with Eli Lilly, Merck, and Gilead acting as key engines for the fund. Merck and Gilead have been steadily rising, helping to power returns, while Thermo Fisher’s strong recent run adds extra fuel. On the flip side, UnitedHealth has been lagging, and Cytokinetics’ more volatile, mixed performance can occasionally weigh on results. With a clear tilt toward pharma and biotech and a global mix that includes Roche, this ETF is a focused bet on cardiovascular and metabolic innovation.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| Eli Lilly & Co | 11.70% | $6.27M | $1.11T | 63.08% | 72 Outperform | |
| Thermo Fisher | 5.80% | $3.11M | $249.58B | 46.87% | 72 Outperform | |
| UnitedHealth | 5.00% | $2.68M | $338.03B | 9.46% | 72 Outperform | |
| Merck & Company | 4.45% | $2.39M | $367.07B | 89.22% | 80 Outperform | |
| ― | 4.18% | $2.24M | ― | ― | ― | |
| Johnson & Johnson | 4.00% | $2.14M | $653.61B | 49.74% | 78 Outperform | |
| Roche Holding | 3.96% | $2.12M | $346.33B | 33.26% | 74 Outperform | |
| Revolution Medicines | 3.69% | $1.98M | $43.93B | 337.90% | 52 Neutral | |
| Cytokinetics | 3.36% | $1.80M | $8.99B | 22.77% | 57 Neutral | |
| Gilead Sciences | 3.30% | $1.77M | $187.15B | 35.15% | 78 Outperform |
HRTS Technical Analysis
Positive
―
Price Trends
37.06
Negative
35.96
Positive
35.39
Positive
Market Momentum
-0.23
Negative
48.00
Neutral
79.41
Neutral
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For HRTS, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of 36.62, equal to the 50-day MA of 37.06, and equal to the 200-day MA of 35.39, indicating a neutral trend. The MACD of -0.23 indicates Negative momentum. The RSI at 48.00 is Neutral, neither overbought nor oversold. The STOCH value of 79.41 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HRTS.
HRTS Peer Comparison
Comparison Results
Performance Comparison
HRTS
Tema Cardiovascular and Metabolic ETF
36.58
4.76
14.96%
OZEM
Roundhill GLP-1 & Weight Loss ETF
―
―
―
PSIL
AdvisorShares Psychedelics ETF
―
―
―
FMED
Fidelity Disruptive Medicine ETF
―
―
―
MEDI
Harbor Health Care ETF
―
―
―
TMED
T. Rowe Price Health Care ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
DisclaimerThis AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents